Risk factors for death among children 0-59 months of age with moderate-to-severe diarrhea in Manhiça district, southern Mozambique.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
15 Apr 2019
Historique:
received: 20 09 2018
accepted: 03 04 2019
entrez: 17 4 2019
pubmed: 17 4 2019
medline: 6 7 2019
Statut: epublish

Résumé

Despite major improvements in child survival rates, the number of deaths due to diarrhea remains unacceptably high. We aimed to describe diarrhea-associated mortality and evaluate risk factors for death among Mozambican children with moderate-to-severe diarrhea (MSD). Between December 2007 and November 2012, children under-five with MSD were enrolled in Manhiça district, as part of the Global Enteric Multicenter study (GEMS). Clinical, epidemiological, and socio-demographic characteristics were collected. Anthropometric measurements were performed and stool samples collected upon recruitment. A follow-up visit ~ 60 days post-enrolment was conducted and verbal autopsies performed in all death cases. Of the 916 MSD-cases analyzed; 90% (821/916) completed 60 days follow-up and 69 patients died. The case fatality rate at follow-up was 8% (69/821), and the mortality rate 10.2 (95%CI: 7.75-13.59) deaths per 1000 persons-week at risk. Nearly half of the deaths 48% (33/69) among study participants clustered within 2 weeks of the onset of diarrhea. Typical enteropathogenic Escherichia coli (typical EPEC) and Cryptosporidium were the two pathogens associated to an increased risk of death in the univariate analysis with (HR = 4.16, p = 0.0461) and (H = 2.84, p = 0.0001) respectively. Conversely, Rotavirus infection was associated to a decreased risk of death (HR = 0.52, p = 0.0198). According to the multivariate analysis, risk factors for death included co-morbidities such as malnutrition (HR = 4.13, p <  0.0001), pneumonia/lower respiratory infection (HR = 3.51, p <  0.0001) or invasive bacterial disease (IBD) (HR = 6.80, p = 0.0009), presenting on arrival with lethargy or overt unconsciousness (HR = 1.73, p = 0.0302) or wrinkled skin (HR = 1.71, p = 0.0393), and cryptosporidium infection (HR = 2.14, p = 0.0038). When restricting the analysis to those with available HIV results (n = 191, 22% of the total study sample), HIV was shown to be a significant risk factor for death (HR = 5.05, p = 0.0009). Verbal autopsies were conducted in 100% of study deaths, and highlighted diarrhea as the main underlying cause of death 39%, (27/69); followed by HIV/AIDS related deaths 29.0% (20/69) and sepsis 11.6% (8/69). Preventive strategies targeting Cryptosporidium, malnutrition and early identification and treatment of associated co-morbidities could contribute to the prevention of the majority of diarrhea associated deaths in Mozambican children.

Sections du résumé

BACKGROUND BACKGROUND
Despite major improvements in child survival rates, the number of deaths due to diarrhea remains unacceptably high. We aimed to describe diarrhea-associated mortality and evaluate risk factors for death among Mozambican children with moderate-to-severe diarrhea (MSD).
METHODS METHODS
Between December 2007 and November 2012, children under-five with MSD were enrolled in Manhiça district, as part of the Global Enteric Multicenter study (GEMS). Clinical, epidemiological, and socio-demographic characteristics were collected. Anthropometric measurements were performed and stool samples collected upon recruitment. A follow-up visit ~ 60 days post-enrolment was conducted and verbal autopsies performed in all death cases.
RESULTS RESULTS
Of the 916 MSD-cases analyzed; 90% (821/916) completed 60 days follow-up and 69 patients died. The case fatality rate at follow-up was 8% (69/821), and the mortality rate 10.2 (95%CI: 7.75-13.59) deaths per 1000 persons-week at risk. Nearly half of the deaths 48% (33/69) among study participants clustered within 2 weeks of the onset of diarrhea. Typical enteropathogenic Escherichia coli (typical EPEC) and Cryptosporidium were the two pathogens associated to an increased risk of death in the univariate analysis with (HR = 4.16, p = 0.0461) and (H = 2.84, p = 0.0001) respectively. Conversely, Rotavirus infection was associated to a decreased risk of death (HR = 0.52, p = 0.0198). According to the multivariate analysis, risk factors for death included co-morbidities such as malnutrition (HR = 4.13, p <  0.0001), pneumonia/lower respiratory infection (HR = 3.51, p <  0.0001) or invasive bacterial disease (IBD) (HR = 6.80, p = 0.0009), presenting on arrival with lethargy or overt unconsciousness (HR = 1.73, p = 0.0302) or wrinkled skin (HR = 1.71, p = 0.0393), and cryptosporidium infection (HR = 2.14, p = 0.0038). When restricting the analysis to those with available HIV results (n = 191, 22% of the total study sample), HIV was shown to be a significant risk factor for death (HR = 5.05, p = 0.0009). Verbal autopsies were conducted in 100% of study deaths, and highlighted diarrhea as the main underlying cause of death 39%, (27/69); followed by HIV/AIDS related deaths 29.0% (20/69) and sepsis 11.6% (8/69).
CONCLUSION CONCLUSIONS
Preventive strategies targeting Cryptosporidium, malnutrition and early identification and treatment of associated co-morbidities could contribute to the prevention of the majority of diarrhea associated deaths in Mozambican children.

Identifiants

pubmed: 30987589
doi: 10.1186/s12879-019-3948-9
pii: 10.1186/s12879-019-3948-9
pmc: PMC6466733
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

322

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : GEMS: Project OPP 38874

Références

Bull World Health Organ. 2001;79(6):546-52
pubmed: 11436477
Stat Med. 2002 Aug 30;21(16):2409-19
pubmed: 12210625
Adv Exp Med Biol. 2004;554:79-87
pubmed: 15384568
Pediatr Infect Dis J. 2006 Apr;25(4):333-8
pubmed: 16567985
Am J Trop Med Hyg. 2007 Mar;76(3):522-7
pubmed: 17360878
Lancet. 2007 Mar 17;369(9565):927-34
pubmed: 17368154
Malar J. 2008 Feb 26;7:36
pubmed: 18302770
Trop Med Int Health. 2008 Jun;13(6):818-26
pubmed: 18397181
Bull World Health Organ. 2008 Sep;86(9):710-7
pubmed: 18797647
Pediatr Infect Dis J. 2009 Feb;28(2):108-13
pubmed: 19131902
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S172-80
pubmed: 19191613
Int J Infect Dis. 2010 Mar;14(3):e220-5
pubmed: 19664950
Trop Med Int Health. 2009 Dec;14(12):1467-74
pubmed: 19793081
Int J Epidemiol. 2010 Apr;39 Suppl 1:i75-87
pubmed: 20348131
Cochrane Database Syst Rev. 2010 Jun 16;(6):CD008563
pubmed: 20556793
Nature. 2010 Oct 28;467(7319):1015
pubmed: 20981062
BMC Public Health. 2011 Apr 13;11 Suppl 3:S15
pubmed: 21501432
BMC Public Health. 2011 Apr 13;11 Suppl 3:S23
pubmed: 21501441
Am J Trop Med Hyg. 2011 Oct;85(4):626-34
pubmed: 21976562
Vaccine. 2012 Apr 27;30 Suppl 1:A173-8
pubmed: 22520128
PLoS One. 2012;7(6):e38321
pubmed: 22675542
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
Clin Infect Dis. 2012 Dec;55 Suppl 4:S262-70
pubmed: 23169939
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Am J Trop Med Hyg. 2013 Jul;89(1 Suppl):41-48
pubmed: 23629927
Public Health Nutr. 2013 Sep;16(9):1565-74
pubmed: 23635423
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
J Pediatr. 2013 Jul;163(1 Suppl):S19-24
pubmed: 23773589
Int J Epidemiol. 2013 Oct;42(5):1309-18
pubmed: 24159076
PLoS One. 2015 May 14;10(5):e0119824
pubmed: 25973880
PLoS One. 2015 Jul 06;10(7):e0132053
pubmed: 26147473
Acta Paediatr. 2015 Dec;104(467):3-13
pubmed: 26249674
PLoS One. 2015 Dec 03;10(12):e0142927
pubmed: 26632843
Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105
pubmed: 27059362
PLoS One. 2016 Apr 26;11(4):e0145943
pubmed: 27116458
PLoS Negl Trop Dis. 2016 May 24;10(5):e0004729
pubmed: 27219054
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
J Infect Dis. 2017 Jun 1;215(11):1666-1672
pubmed: 28430997
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Lancet. 2018 Feb 24;391(10122):801-812
pubmed: 29254859
Parasit Vectors. 2018 Jan 9;11(1):28
pubmed: 29316950
PLoS One. 2018 Feb 2;13(2):e0184249
pubmed: 29394247
Int J Infect Dis. 2018 Aug;73:10-17
pubmed: 29852260
Am J Epidemiol. 1988 Jul;128(1):93-105
pubmed: 3381838
Hum Nutr Clin Nutr. 1982;36(4):279-88
pubmed: 6815136

Auteurs

Sozinho Acácio (S)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.
Ministério da Saúde, Instituto Nacional de Saúde, Av. Eduardo Mondlane n° 1008, C.P, 264, Maputo, Moçambique.

Inácio Mandomando (I)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.
Ministério da Saúde, Instituto Nacional de Saúde, Av. Eduardo Mondlane n° 1008, C.P, 264, Maputo, Moçambique.

Tacilta Nhampossa (T)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.
Ministério da Saúde, Instituto Nacional de Saúde, Av. Eduardo Mondlane n° 1008, C.P, 264, Maputo, Moçambique.

Llorenç Quintó (L)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosselló 132, 5-2ª, 08036, Barcelona, Spain.

Delfino Vubil (D)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.

Charfudin Sacoor (C)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.

Karen Kotloff (K)

Center for Vaccine Development (CVD), University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.

Tamer Farag (T)

Center for Vaccine Development (CVD), University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.

Dilruba Nasrin (D)

Center for Vaccine Development (CVD), University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.

Eusébio Macete (E)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.
Ministério da Saúde, Instituto Nacional de Saúde, Av. Eduardo Mondlane n° 1008, C.P, 264, Maputo, Moçambique.

Myron M Levine (MM)

Center for Vaccine Development (CVD), University of Maryland School of Medicine, 655 W. Baltimore Street, Baltimore, MD, 21201, USA.

Pedro Alonso (P)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosselló 132, 5-2ª, 08036, Barcelona, Spain.

Quique Bassat (Q)

Centro de Investigação em Saúde de Manhiça (CISM), Rúa 12, Vila da Manhiça, 1929, Maputo, CP, Mozambique. quique.bassat@manhica.net.
ISGlobal, Hospital Clínic - Universitat de Barcelona, Rosselló 132, 5-2ª, 08036, Barcelona, Spain. quique.bassat@manhica.net.
ICREA, Pg. Lluís Companys 23, 08010, Barcelona, Spain. quique.bassat@manhica.net.
Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, Pg. Sant Joan de Déu 2, 08950, Barcelona, Esplugues de Llobregat, Spain. quique.bassat@manhica.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH